Search Results - "Tonato, M."

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference by Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., Grunberg, S. M., Hesketh, P. J., Jordan, K., Kris, M. G., Maranzano, E., Molassiotis, A., Morrow, G., Olver, I., Rapoport, B. L., Rittenberg, C., Saito, M., Tonato, M., Warr, D.

Get full text

Heine H. Hansen, 1938–2011: a European oncologist by Tonato, M.

Get full text

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer by Scagliotti, G V, De Marinis, F, Rinaldi, M, Crinò, L, Gridelli, C, Ricci, S, Matano, E, Boni, C, Marangolo, M, Failla, G, Altavilla, G, Adamo, V, Ceribelli, A, Clerici, M, Di Costanzo, F, Frontini, L, Tonato, M

“…To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for…”
Get full text

The Effect of an Infant Formula Supplemented with AA and DHA on Fatty Acid Levels of Infants with Different FADS Genotypes: The COGNIS Study by Salas Lorenzo, Isabel, Chisaguano Tonato, Aida M, de la Garza Puentes, Andrea, Nieto, Ana, Herrmann, Florian, Dieguez, Estefanía, Castellote, Ana I, López-Sabater, M Carmen, Rodríguez-Palmero, Maria, Campoy, Cristina

“…Polymorphisms in the fatty acid desaturase (FADS) genes influence the arachidonic (AA) and docosahexaenoic (DHA) acid concentrations (crucial in early life)…”
Get full text

Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer by Cappuzzo, Federico, Magrini, Elisabetta, Ceresoli, Giovanni Luca, Bartolini, Stefania, Rossi, Elisa, Ludovini, Vienna, Gregorc, Vanesa, Ligorio, Claudia, Cancellieri, Alessandra, Damiani, Stefania, Spreafico, Anna, Paties, Carlo Terenzio, Lombardo, Laura, Calandri, Cesare, Bellezza, Guido, Tonato, Maurizio, Crinò, Lucio

“…Background: Gefitinib, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has activity against approximately 10% of unselected…”
Get full text

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients by Ludovini, V., Bellezza, G., Pistola, L., Bianconi, F., Di Carlo, L., Sidoni, A., Semeraro, A., Del Sordo, R., Tofanetti, F.R., Mameli, M.G., Daddi, G., Cavaliere, A., Tonato, M., Crinò, L.

“…Insulin-like growth factor receptor-1 (IGFR-1) represents a novel molecular target in non-small-cell lung cancer (NSCLC). IGFR-1 and epidermal growth factor…”
Get full text

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project by CRINO, L, SCAGLIOTTI, G. V, SASSI, M, BARNI, S, RAVAIOLI, A, ADAMO, V, PORTALONE, L, CRUCIANI, G, MASOTTI, A, FERRARA, G, GOZZELINO, F, TONATO, M, RICCI, S, DE MARINIS, F, RINALDI, M, GRIDELLI, C, CERIBELLI, A, BIANCO, R, MARANGOLO, M, DI COSTANZO, F

“…To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) chemotherapy in patients with stage IIIB (limited to T4 for pleural…”
Get full text

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study by Crinò, L, Scagliotti, G, Marangolo, M, Figoli, F, Clerici, M, De Marinis, F, Salvati, F, Cruciani, G, Dogliotti, L, Pucci, F, Paccagnella, A, Adamo, V, Altavilla, G, Incoronato, P, Trippetti, M, Mosconi, A M, Santucci, A, Sorbolini, S, Oliva, C, Tonato, M

“…The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination…”
Get more information

Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients by LUDOVINI, V, SIDONI, A, RODINO, C, SABBATINI, R, MAZZOCCHI, B, BUCCIARELLI, E, TONATO, M, COLOZZA, M, PISTOLA, L, BELLEZZA, G, DE ANGELIS, V, GORI, S, MOSCONI, A. M, BISAGNI, G, CHERUBINI, R, BIAN, A. Rosa

“…In this study, we retrospectively evaluated the expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in 228 and 213 specimens,…”
Get full text

Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy

“…The administration of moderately emetogenic drugs such as cyclophosphamide, doxorubicin, epirubicin, and carboplatin often causes nausea and vomiting within 24…”
Get full text

Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference by Roila, F., Del Favero, A., Gralla, R.J., Tonato, M.

“…Background: The need to review and summarize the evidence concerning preventive treatment of cancer chemotherapy- and radiotherapy-induced emesis. Design:…”
Get full text

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer by GORI, S, COLOZZA, M, CRINO, L, TONATO, M, MOSCONI, A. M, FRANCESCHI, E, BASURTO, C, CHERUBINI, R, SIDONI, A, RULLI, A, BISACCI, C, DE ANGELIS, V

“…Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo. In previous experiences, weekly…”
Get full text

Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study by Gatzemeier, U., Shepherd, F.A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H.J.M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., Burkes, R.L., Gottfried, M., Voi, M.

“…Gemcitabine is a novel nucleoside analogue with activity in solid tumours. This study assessed the objective response rate to gemcitabine given weekly…”
Get full text

Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer by Minotti, V, Crino′, L, Meacci, M.L, Corgna, E, Darwish, S, Palladino, M.A, Betti, M, Tonato, M

“…Twenty-three patients with brain metastases from non-small cell lung cancer (NSCLC) (median age 62 years, Karnofsky PS 50-100) were treated with cisplatin (100…”
Get full text

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy by Novello, S., Kielhorn, A., Stynes, G., Selvaggi, G., De Marinis, F., Maestri, A., Foggi, P., Tilden, D., Tonato, M., Crinò, L., Rinaldi, M., Migliorino, A.M., Scagliotti, G.V.

“…A retrospective cost-minimisation analysis was conducted comparing novel chemotherapies for the treatment of chemo-naive patients with locally advanced,…”
Get full text

A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial by Rinaldi, M., Crinò, L., Scagliotti, G. V., Mosconi, A. M., De Marinis, F., Gridelli, C., Selvaggi, G., Della Giulia, M., Darwish, S., Porrozzi, S., Novello, S., Cipri, A., Bartolucci, R., Calandri, C., Tonato, M.

“…Background: To explore a new schedule of gemcitabine–cisplatin (GP) combination therapy using two different cisplatin doses in patients with advanced…”
Get full text

The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer by Rosell, R, Tonato, M, Sandler, A

“…Three separate phase III randomized studies were conducted to compare the efficacy of a gemcitabine plus cisplatin combination (GC) with other chemotherapy…”
Get more information

5-HT3 receptor antagonists: Differences and similarities by Roila, F., Ballatori, E., Tonato, M., Favero, A.Del

“…Differences among 5-HT3 receptor antagonists have been reported in pharmacological studies with regard to selectivity of receptor binding, potency, duration of…”
Get full text

Methodology of antiemetic trials: a review by Tonato, M, Roila, F, Del Favero, A

“…Chemotherapy-related nausea and vomiting can be controlled with available antiemetics in a high percentage of patients, while emesis remains a critical problem…”
Get more information

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone by Roila, F, Tonato, M, Cognetti, F, Cortesi, E, Favalli, G, Marangolo, M, Amadori, D, Bella, M A, Gramazio, V, Donati, D

“…Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated…”
Get more information